F8 and hemophilia A: Approval has been granted by both the European Medicines Agency(EMA) and FDA for the treatment of severe Hemophilia A. Based on Phase III clinical trials, a substantial increase in FVIII or FIX levels was observed in the majority of treated patients (Mahlangu et al., 2023; Pipe et al., 2023).